Efficacy News and Research

RSS
Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference

Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

PointCross releases SDIS technology to BioPharma industry

PointCross releases SDIS technology to BioPharma industry

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Surveyed cardiologists, PCPs perceive Crestor comparable to Lipitor in ability to reduce mortality

Surveyed cardiologists, PCPs perceive Crestor comparable to Lipitor in ability to reduce mortality

Xanodyne to withdraw propoxyphene-containing products from the U.S. market

Xanodyne to withdraw propoxyphene-containing products from the U.S. market

Children's Surgical Centre offers no-cost surgery for children with frontoethmoidal meningoencephalocele

Children's Surgical Centre offers no-cost surgery for children with frontoethmoidal meningoencephalocele

Russian-trained microbiologist recommends tips for consumers to achieve effective results from probiotics

Russian-trained microbiologist recommends tips for consumers to achieve effective results from probiotics

USC Norris designated Phase I Clinical Trial Center of Excellence

USC Norris designated Phase I Clinical Trial Center of Excellence

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Recent releases in Global Health

Recent releases in Global Health

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.